Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate.
We have investigated the role of dihydrofolate (H2PteGlu) accumulation in the inhibition of de novo purine synthesis by methotrexate (MTX) in human MCF-7 breast cancer cells. Previous studies have shown that cytotoxic concentrations of MTX that inhibit dihydrofolate reductase produce only minimal depletion of the reduced folate cofactor, 10-formyltetrahydrofolate, required for purine synthesis. At the same time, de novo purine synthesis is totally inhibited. In these studies, we show that 10 microM MTX causes inhibition of purine synthesis at the step of phosphoribosylaminoimidazolecarboxamide (AICAR) transformylase, as reflected in a 2-3-fold expansion of the intracellular AICAR pool. The inhibition of purine synthesis coincides with the rapid intracellular accumulation of H2PteGlu, a known inhibitor of AICAR transformylase. When the generation of H2PteGlu is blocked by pretreatment with 50 microM 5-fluorodeoxyuridine (FdUrd), an inhibitor of thymidylate synthase, MTX no longer causes inhibition of purine synthesis. Intermediate levels of H2PteGlu produced in the presence of lower (0.1-10 microM) concentrations of FdUrd led to proportional inhibition of purine biosynthesis, and the exogenous addition of H2PteGlu to breast cells in culture re-established the block in purine synthesis in the presence of FdUrd and MTX. The early phases of inhibition of purine biosynthesis could be ascribed only to H2PteGlu accumulation. MTX polyglutamates, also known to inhibit AICAR transformylase, were present in breast cells only after 6 h of incubation with the parent compounds and were not formed in cells preincubated with FdUrd. The lipid-soluble antifolate trimetrexate, which does not form polyglutamates, produced modest 10-formyltetrahydrofolate depletion, but caused marked H2PteGlu accumulation and a parallel inhibition of purine biosynthesis. This evidence leads to the conclusion that MTX and the lipid-soluble analog trimetrexate cause inhibition of purine biosynthesis through the accumulation of H2PteGlu behind the blocked dihydrofolate reductase reaction.
D000217:Acyltransferases / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000494:pharmacology; D001943:Breast Neoplasms; D002250:Carbon Radioisotopes; D002460:Cell Line; D005260:Female; D005467:Floxuridine / Q000494:pharmacology; D005492:Folic Acid / Q000378:metabolism; D005998:Glycine / Q000378:metabolism; D006801:Humans; D019877:Hydroxymethyl and Formyl Transferases; D007700:Kinetics; D008727:Methotrexate / Q000031:analogs & derivatives / Q000096:biosynthesis / Q000302:isolation & purification / Q000494:pharmacology*; D051027:Phosphoribosylaminoimidazolecarboxamide Formyltransferase; D011099:Polyglutamic Acid / Q000031:analogs & derivatives / Q000096:biosynthesis / Q000302:isolation & purification; D011687:Purines / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D011799:Quinazolines / Q000494:pharmacology; D016597:Trimetrexate
D000970:Antineoplastic Agents; D002250:Carbon Radioisotopes; D011687:Purines; D011799:Quinazolines; D005467:Floxuridine; D011099:Polyglutamic Acid; C014085:methotrexate polyglutamate; D005492:Folic Acid; D019877:Hydroxymethyl and Formyl Transferases; D051027:Phosphoribosylaminoimidazolecarboxamide Formyltransferase; D000217:Acyltransferases; D005998:Glycine; D016597:Trimetrexate; D008727:Methotrexate